Cancer Cachexia: Molecular Mechanisms and Therapeutic Approaches
Boston, September 21-23, 2012

Friday, September 21, 2012

1:00 pm    Registration and Poster Set-up    Belvidere Foyer
3:00-3:10 pm    Introductory Remarks    Maverick A&B
Denis Guttridge, PhD
Professor, Molecular Virology, Immunology
and Medical Genetics
The Ohio State University
Columbus, Ohio

4:10-5:10 pm    (Keynote Address) - Mechanisms of muscle atrophy and hypertrophy    Adams A&B
David Glass, PhD
Global Head, Musculoskeletal Diseases Group
Novartis Institutes for Biomedical Research
Boston, MA
Q/A –

5:15-6:45 pm    Welcoming Reception
Fenway Room

7:00 pm    Poster Viewing    Maverick A&B

Saturday, September 22, 2012

7:30-8:30 am    Continental Breakfast
Pre-Assembly

Session 1
Clinical Manifestations of Cancer Cachexia
(Chair: Aminah Jatoi, MD)

8:30-9:00 am    Classification of cancer cachexia
Kenneth Fearon, MD, MBBch. Hons.
Professor of Surgical Oncology
University of Edinburgh
United Kingdom
Q/A -

9:00-9:30 am    Body composition and prognostication in cancer
Vickie Baracos, PhD
Professor and Alberta Cancer Foundation Chair in Palliative Medicine
Department of Oncology
University of Alberta
Edmonton Alberta, Canada
Q/A –
9:30-9:45 am  (Short Talk 1) Cancer Cachexia: fitting classifications into clinical practice
Maurizio Muscaritoli, MD
Department of Clinical Medicine
University La Sapienza
Rome, Italy
Q/A

9:45-10:00 am  (Short Talk 2) Anti-cachexia melanocortin peptide with oral activity
Kenneth A. Gruber, PhD
Tensive Controls, Inc
Columbia, Missouri
Q/A –

10:00-10:30 am  Coffee Break

10:30 – 11:00 am  Onset and progression of cancer cachexia, results from the Montreal longitudinal study
Bruno Gagnon, MD
Assistant Professor
Department of Medicine and Oncology
Faculty of Medicine, McGill University
Montreal, Quebec, Canada
Q/A -

11:00-11:30 am  Interactions between antineoplastic therapy and cachexia: a medical oncology perspective”
Michael Sawyer, MD
Associate Professor, Department of Medical Oncology
University of Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada
Q/A-

11:30-11:45 am  (Short Talk 3) Physical functions and sexual dimorphism
Nathan Stephens, MD
Surgical Research Fellow, Tissue Injury & Repair
University of Edinburgh
Edinburgh, United Kingdom
Q/A

11:45-12:00 pm  (Short Talk 4) Progressive skeletal muscle wasting and long-term impairment of mitochondrial function following repeated cyclical administration of doxorubicin and dexamethasone
Thomas Jagoe, MD, PhD
Assistant Professor
Department of Oncology
McGill University
Montreal, Quebec, Canada
12:00 noon
Lunch
Fenway Room

Session 2
Mechanisms of Muscle Wasting in Cancer Cachexia (Part 1)
(Chair: Denis Guttridge, PhD)

1:30-2:00 pm
New insights into the molecular mechanisms of muscle wasting and cachexia
Alfred Goldberg, MD
Professor
Department of Cell Biology
Harvard Medical School
Boston, MA
Q/A -

2:00-2:30 pm
Mechanisms of muscle wasting in cancer
Josep Argiles, PhD
Professor
University of Barcelona
Barcelona, Spain
Q/A -

2:30-3:00 pm
A novel pathway in TGFbeta signaling that controls muscle cachexia
Marco Sandri, MD
Assistant Professor
Department of Biomedical Science
University of Padova
Padova, Italy
Q/A -

3:00-5:00 pm
Poster Session (Judging) + Free Time
Maverick A&B
Adams A&B

Session 3:
Mechanisms of Muscle Wasting in Cancer Cachexia, Part II
(Chair: Marion Couch, MD, PhD)

5:00-5:30 pm
Cellular signaling in cancer cachexia
Denis Guttridge, PhD
Professor
Department of Molecular Virology, Immunology and Medical Genetics
The Ohio State University
Columbus, Ohio
Q/A -
5:30-6:00 pm  The role of triglyceride lipases in cancer cachexia
Gerald Hoelfer, MD
Professor of Pathology
Institute of Pathology
Medical University of Graz
Graz, Austria
Q/A-

6:00-6:15 pm  (Short Talk 1) – Stat3 in cancer cachexia
Teresa Zimmers, PhD
Associate Professor
Department of Cell Biology
Thomas Jefferson University
Philadelphia, Pennsylvania
Q/A -

6:15-6:30 pm  (Short Talk 2) - PGC-1α isoform (PGC-1α 4) regulates skeletal muscle wasting during cancer-induced cachexia
James White, PhD
Research Fellow
Dana Farber Cancer Center
Harvard Medical School
Cambridge, MA
Q/A -

6:30-6:45 pm  (Short Talk 3) – The translation inhibitor pateamine A Prevents cachexia-induced muscle wasting in mice
Eddine Gallouzi, PhD
Associate Professor
Department of Biochemistry
Goodman Cancer Center, McGill University
Montreal, Quebec, Canada
Q/A -

7:00 pm  Banquet
Fenway Room

9:00 pm  Evening Reception/Poster Viewing
Maverick A&B
Adams A&B

Sunday, September 23, 2012

7:30-8:30 am  Breakfast
Fenway Room

Session 4:
Involvement of Non-Muscle Tissue in Cancer Cachexia
(Chair: Ken Fearon, MD)
8:30-9:00 am  
**Cardiac muscle wasting and fibrosis in cancer**  
Jochen Springer, PhD  
Center for Cardiovascular Research  
Charite Campus Mitte  
Berlin, Germany  
Q/A -

9:00-9:30 am  
**Chemotherapy-induced cardiotoxicity**  
Thomas Force, MD  
Professor  
Clinical Director Jefferson Center for Translational Medicine  
Thomas Jefferson University  
Philadelphia, Pennsylvania  
Q/A-

9:30-9:45 am  
**Short Talk 1 – Cause of death in cancer cachexia – the impact of CV drugs**  
Andrew J. Stewart Coats, PhD  
Professor and CEO, Norwich Research Park  
Norwich, UK  
Q/A

9:45-10:00 am  
**Short Talk 2 – Ryanodine receptor 1 remodeling in cancer associated muscle dysfunction**  
David Waning, PhD  
Assistant Research Professor  
Indiana University School of Medicine  
Indianapolis, Indiana  
Q/A

10:00-10:30 am  
**Coffee Break**

10:30-11:00 am  
**Mechanisms of cardiac atrophy in cancer**  
Monte Willis, MD  
Associate Professor  
McAllister Heart Institute  
Department of Pathology and Laboratory Medicine  
University of North Carolina  
Chapel Hill, North Carolina  
Q/A

11:00-11:30 am  
**Neuroendocrine influences in cachexia**  
Daniel Marks, MD  
Associate Professor  
Doernbecher Children’s Hospital  
Oregon Health and Sciences University  
Portland, Oregon  
Q/A -
11:30-11:45 am  *(Short Talk 3) – NF-κB signaling proteins and transcription factors required for cancer-induced muscle wasting*  Belvidere
Susan Kandarian, PhD
Professor, Department of Health Sciences
Boston University
Boston, MA
Q/A

12:00-1:30 pm  *Lunch*  Fenway Room

**Session 5:**
**Therapeutic Targets and Clinical Trials in Cancer Cachexia**  Belvidere
*(Chair: Vickie Baracos, PhD)*

1:30-2:00 pm  Targeting myostatin as a potential therapy for cancer cachexia  Ronenn Roubenoff, MD
Novartis/Tufts University
Boston, MA
Q/A -

2:00-2:15 pm  *(Short Talk 1)Targeting ghrelin system for the management of cachexia/anorexia syndrome*  Egidio Del Fabbro, MD
Associate Professor
Department of Internal Medicine
Virginia Commonwealth University
Richmond, Virginia
Q/A –

2:15-2:45 pm  Choosing the right clinical endpoints for a cachexia trial  Florian Strasser, MD, ABHPM
Associate Professor
Oncological Palliative Medicine
Cantonal Hospital
St. Gallen, Switzerland
Q/A –

2:45-3:00 pm  *(Short Talk 2) – Cancer cachexia: Evaluation of body composition using CT scans and identification of genetic markers*  Neil Johns, MBBS, BSC, MRCS
Specialty Registrar in General Surgery
Clinical Surgery School of Clinical Sciences
University of Edinburgh
Edinburgh, UK

3:00-3:30 pm  *Coffee Break*  Pre-Assembly
3:30-4:00 pm  Treatment development for cancer cachexia: current status, statistical issues & avoidable errors
Stefan Anker, MD, PhD
Professor of Cardiology and Cachexia Research
Department of Cardiology
Charite Campus Virchow-Klinikum
Berlin, Germany
Q/A –

4:00-4:30 pm  The challenges of recruiting and retaining patients onto cancer cachexia trials
Aminah Jatoi, MD
Professor
Department of Oncology
Mayo Clinic
Rochester, Minnesota
Q/A –

4:30-4:45 p.m.  (Short Talk 3) – Molecular mechanisms underlying reduced knee extensor function and walking endurance in cancer Patients: diminished myosin-actin cross-bridge kinetics
Michael Toth, PhD
Department of Medicine
University of Vermont College of Medicine
Burlington, Vermont
Q/A –

4:45-5:30 pm  Panel Discussion (led by)
Marion Couch, MD, PhD
Professor and Director
Head and Neck Research, Department of Otolaryngology
University of Vermont
Burlington, Vermont

5:30-5:40 pm  Closing Remarks (Denis Guttridge)